Call Us for Support
+91 9654860915
Google Reviews
4.8
Call Us for Support
+91 9654860915
Sourced directly from the authorized manufacturer network to ensure authenticity and quality.
You can also access detailed information by clicking Login in the website header.
Supplied with complete CDSCO-approved import and customs documentation, including Form 12A & 12B, CDEC, GST Bill of Entry, Commercial Invoice, and Packing List.
Manufacturer / Innovator:
USA
Regulatory Approval:
N/A
Your Trustedworthy Partner For Named Patient Program
Over a decade of trusted expertise in Named Patient Access to innovative and life-saving medicines.
100% CDSCO-compliant processes ensuring safe, ethical, and responsible medicine access.
Medicines sourced from authorized manufacturers with full batch traceability.
EU-GDP compliant warehousing for secure, quality-controlled global distribution.
Temperature-controlled logistics ensuring safe, reliable, and timely medicine delivery.
Xpovio (selinexor) is a selective inhibitor of nuclear export (SINE) approved by the FDA for adult patients with multiple myeloma: in combination with bortezomib and dexamethasone for patients who have received at least one prior therapy, or in combination with dexamethasone alone for patients who have received at least four prior therapies and whose disease is refractory to at least two proteasome inhibitors, two immunomodulatory agents, and an anti-CD38 monoclonal antibody. Xpovio is the US brand of the same active ingredient marketed in the EU and UK as Nexpovio.
Xpovio blocks exportin 1 (XPO1), a protein that transports tumor suppressor proteins out of the cell nucleus. By inhibiting XPO1, Xpovio helps restore the normal function of these tumor suppressor proteins within cancer cells, leading to cell cycle arrest and cancer cell death.
Xpovio is used across multiple treatment stages for multiple myeloma, from patients who have received one prior therapy to heavily pretreated patients with disease refractory to multiple drug classes.
In combination with bortezomib and dexamethasone, the typical dose is 100 mg orally once weekly. In combination with dexamethasone alone, the typical dose is 80 mg orally on Days 1 and 3 of each week.
Xpovio does not carry a formal FDA boxed warning, despite a significant toxicity profile. Patients and prescribers should be aware of the following important safety information.
Frequent blood count monitoring is required throughout treatment, as low platelet and white blood cell counts are common and may require dose modification or supportive care.
Nausea, vomiting, and diarrhea are common. Prophylactic antiemetic therapy is recommended before and during treatment.
Low sodium levels and neurological adverse effects, including confusion and dizziness, have been reported and should be monitored during treatment.
Serious infections and cataract development have been observed. Embryo-fetal toxicity is also a concern, and effective contraception should be used during treatment.
Step 1 – Search & request your medicine: The patient or treating doctor submits a request with basic details to initiate the access process.
Step 2 – Verification & eligibility review: The team verifies availability and reviews eligibility against regulatory and clinical requirements to ensure a compliant pathway.
Step 3 – Receive quote & delivery timeline: A transparent quotation is shared, covering medicine cost, logistics, and a clear delivery timeline.
Step 4 – Regulatory approval process: Assistance is provided to secure the approvals and documentation required for legal cross-border access.
Step 5 – Temperature-controlled import & handling: The medicine is sourced and transported under strict GDP-compliant conditions to maintain product integrity.
Step 6 – Secure delivery: The medicine is delivered to the patient or treating hospital, with updates provided at each stage.
Note: From request to delivery, every step is designed to ensure your treatment reaches you safely, compliantly, and without unnecessary delays.
Xpovio is manufactured and marketed by Karyopharm Therapeutics Inc. in the United States. It is not separately marketed in the EU or UK — the identical selinexor active ingredient is sold there under the brand name Nexpovio. NPP sources Xpovio through authorized US distribution channels for patients seeking named-patient import into India.
Patients typically need a valid prescription from a treating hematologist-oncologist confirming multiple myeloma diagnosis and prior treatment history. NPP's regulatory team assists in preparing and verifying the documentation needed for a compliant import.
As an FDA-approved therapy for multiple myeloma, Xpovio is sourced through authorized US channels and imported under GDP-compliant logistics to preserve product quality throughout transit.
NPP sources Xpovio directly from authorized US pharmaceutical distributors to ensure product authenticity and full traceability. Every shipment is handled under Good Distribution Practice (GDP) conditions from origin to the patient's doorstep.
Xpovio should be stored at or below 30°C, and this condition is maintained throughout transit.
Once documentation and regulatory approvals are in place, delivery timelines are communicated transparently at the time of quotation, accounting for import clearance and last-mile logistics to the patient's city.
Patients across India can access Xpovio through NPP's regulated import pathway, with hematology-oncology specialists in major cities supporting the treatment process.
Leading hospitals in Mumbai support hematology-oncology care coordination and documentation for Xpovio access.
Delhi's major hospitals assist patients with prescription support and documentation for Xpovio.
Bangalore's specialist network offers access coordination for eligible multiple myeloma patients seeking Xpovio.
Chennai-based hematology specialists coordinate Xpovio access alongside comprehensive myeloma care.
Hyderabad's care institutions support patients pursuing Xpovio therapy.
Kolkata's specialist centers help coordinate documentation and treatment access for Xpovio.
Pune-based specialists assist with prescription support and Xpovio treatment planning.
Ahmedabad's specialty hospitals support the import and treatment process for Xpovio.
Kochi's specialist units assist patients with the documentation needed for Xpovio access.
Chandigarh's care centers support Xpovio treatment coordination for patients from North India.
Jaipur's specialists help patients navigate the Xpovio access process.
Lucknow-based centers assist patients pursuing Xpovio therapy.
Bhubaneswar's institutions support access to Xpovio for eligible patients.
Guwahati's specialists help coordinate Xpovio access for patients across the Northeast.
Patients in other cities across India can also access Xpovio through NPP's nationwide coordination network.
Written By: Nitin Goswami, Senior Medical Content Writer
Last Updated: 15 September 2026
Sources: FDA
Medically Reviewed By: Shilpi Banerjee, Registered Pharmacist (M.Pharm)
Last Updated: 15 September 2026
Our specialists are here to guide you through every step of the medicine access process.
Mail Us At:
info@namedpatientprogram.comContact Us:
+91 9654860915Send us a message
